Verve Entered into an Exclusive Research Collaboration with Eli Lilly to Advance In Vivo Gene Editing Program Targeting Lp(a) for Atherosclerotic Cardiovascular Disease
Shots:
- Verve will receive $60M in up front & equity investment & is also eligible to receive ~$465M in research, development, and commercial milestones along with royalties on global net sales. The companies focused to advance preclinical stage in vivo gene editing program targeting lipoprotein(a) (Lp(a))
- Verve gets the opt-in rights to co-fund and share margins globally on the Lp(a) program & will advance the R&D of the Lp(a) program upon the completion of P-I clinical trials. Lilly will lead the subsequent development, manufacturing, and commercialization of the Lp(a) program
- The companies continue to develop a much-needed treatment option for patients with elevated levels of Lp(a)
Ref: Globenewswire | Image: Eli Lilly
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
